Minister of State at the Department of Enterprise and Innovation Pat Breen TD announced that Takeda Pharmaceutical Company Limited (TSE: 4502) is to create up to 70 new jobs and invest €25m in the construction of a new regenerative medicine facility at its site in Grange Castle.
The investment by Takeda will expand their Grange Castle site’s existing footprint, with the construction of a new standalone modular cell therapy facility dedicated to manufacturing a novel stem cell therapy. The investment will also create 70 temporary construction jobs. The facility will be in commercial operation by 2021. This investment is supported by the Irish Government through IDA Ireland.
The largest pharmaceutical company in Japan, Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan. In 2017 Takeda also announced a €40m investment in the construction of a stand-alone production facility for the manufacture of part of their Oncology portfolio at Grange Castle.
Welcoming the announcement Minister of State Pat Breen TD said: "The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors.
"Takeda's decision to invest in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I'm delighted that this investment will bring a further 70 jobs to the company's existing Clondalkin facility."
